TSX futures tick up after index logs fresh record high close
Investing.com - H.C. Wainwright lowered its price target on Orchestra BioMed Inc. (NASDAQ:OBIO) to $10.00 from $12.00 on Thursday, while maintaining a Buy rating on the stock. Currently trading at $2.72, the company maintains strong gross profit margins of 93% and holds more cash than debt, according to InvestingPro data.
The price target adjustment follows Orchestra BioMed’s recent publication in the Journal of the American College of Cardiology: Clinical Electrophysiology, which demonstrated favorable hemodynamic effects of AVIM therapy in pacemaker-indicated patients with uncontrolled hypertension.
The published data showed that AVIM therapy reduced systolic blood pressure acutely by decreasing cardiac preload and effective arterial elastance, while also improving left ventricular end-diastolic and end-systolic volumes. Chronically administered AVIM therapy demonstrated sustained reductions in systolic blood pressure and end-diastolic volume.
This publication followed another study published in August 2025 in JACC: Advances, showing AVIM therapy significantly improved cardiac function in patients with isolated systolic hypertension and diastolic dysfunction, key contributors to heart failure with preserved ejection fraction.
H.C. Wainwright noted that its estimated market value for Orchestra BioMed has increased to $591 million, but projected shares outstanding in 12 months increased to 59.1 million following recent financings, resulting in the adjusted price target of $10 per share. The company’s current market capitalization stands at $146 million, with analyst targets ranging from $12 to $20 per share.
In other recent news, Orchestra BioMed Holdings, Inc. announced positive data from a study published in the Journal of the American College of Cardiology: Clinical Electrophysiology. The study highlighted the favorable effects of its atrioventricular interval modulation (AVIM) therapy, which significantly reduced systolic blood pressure in patients with uncontrolled hypertension who require pacemakers. Additionally, a new study published in JACC: Advances showed that AVIM therapy improved cardiac function among patients with hypertension and diastolic dysfunction. In another development, the U.S. Food and Drug Administration approved a protocol update for Orchestra BioMed’s BACKBEAT global pivotal study, greatly expanding the patient eligibility criteria. This change could increase the eligible patient pool by more than 24 times compared to the original design. Despite these advancements, BTIG downgraded Orchestra BioMed’s stock rating from Buy to Neutral, citing concerns over recent dilutive equity financing and strategic funding arrangements. Furthermore, Orchestra BioMed announced a public offering of its common stock and pre-funded warrants, with an option for underwriters to purchase additional shares. These developments reflect a dynamic period for the company, with both advancements in therapy and strategic financial maneuvers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.